Contributions of phosphatidylserine-positive platelets and leukocytes and microparticles to hypercoagulable state in gastric cancer patients

Tumor Biology

Volumn 37, Issue 6, 2016, Pages 7881-7891

  Yang, Chunfa ^a   Ma, Ruishuang ^a   Jiang, Tao ^a   Cao, Muhua ^a   Zhao, Liangliang ^a   Bi, Yayan ^a   Kou, Junjie ^a   Shi, Jialan ^a   Zou, Xiaoming ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Microparticles; Phosphatidylserine; Prothrombotic state; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; LACTADHERIN; PHOSPHATIDYLSERINE; PROCOAGULANT; TENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; LAPAROTOMY; LEUKOCYTE; LEUKOCYTE COUNT; MALE; MEMBRANE MICROPARTICLE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN TARGETING; RADICAL RESECTION; STOMACH CANCER; THROMBOCYTE; THROMBOCYTE COUNT; BLOOD; BLOOD CLOTTING; COMPLICATION; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; STOMACH TUMOR; THROMBOPHILIA;

ADULT; BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; THROMBOPHILIA;

EID: 84951866773     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4667-5     Document Type: Article

References (46)

1. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64.
2. Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost. 2010;8:540–7.
3. White RH, Chew H, Wun T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res. 2007;120 Suppl 2:S29–40.
4. Di Micco P, Romano M, Niglio A, et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2001;33:546–50.
5. Fidan E, Kavgaci H, Orem A, et al. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumor Biol. 2012;33:1519–25.
6. Kwon HC, Oh SY, Lee S, et al. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.
7. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10:355–62.
8. Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827–33.
9. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA. 2012;109:13076–81.
10. Shao B, Wahrenbrock MG, Yao L, et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011;118:4015–23.
11. Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–62.
12. Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res. 2005;44:207–34.
13. Delaney MK, Liu J, Kim K, et al. Agonist-induced platelet procoagulant activity requires shear and a Rac1-dependent signaling mechanism. Blood. 2014;124:1957–67.
14. Wahid ST, Marshall SM, Thomas TH. Increased platelet and erythrocyte external cell membrane phosphatidylserine in type 1 diabetes and microalbuminuria. Diabetes Care. 2001;24:2001–3.
15. Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost. 2012;107:681–9.
16. Tan X, Shi J, Fu Y, et al. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost. 2013;109:1025–32.
17. Baran J, Baj-Krzyworzeka M, Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010;59:841–50.
18. Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–91.
19. Yamashita H, Kitayama J, Ishikawa M, et al. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol. 2007;95:324–31.
20. Lo L, Valentine H, Harrison J, et al. Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population. Br J Cancer. 2012;107:1125–30.
21. Hernandez C, Orbe J, Roncal C, et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost. 2013;110:598–608.
22. Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. Blood. 2003;101:2628–36.
23. Shi J, Heegaard CW, Rasmussen JT, et al. Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature. Biochim Biophys Acta. 2004;1667:82–90.
24. Gao C, Xie R, Li W, et al. Endothelial cell phagocytosis of senescent neutrophils decreases procoagulant activity. Thromb Haemost. 2013;109:1079–90.
25. Zhou J, Liu S, Ma M, et al. Procoagulant activity and phosphatidylserine of amniotic fluid cells. Thromb Haemost. 2009;101:845–51.
26. Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost. 2009;7:190–7.
27. Aleman MM, Gardiner C, Harrison P, et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9:2251–61.
28. Sarlon-Bartoli G, Bennis Y, Lacroix R, et al. Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. J Am Coll Cardiol. 2013;62:1436–41.
29. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33:1469–79.
30. Augustine D, Ayers LV, Lima E, et al. Dynamic release and clearance of circulating microparticles during cardiac stress. Circ Res. 2014;114:109–13.
31. van Doormaal F, Kleinjan A, Berckmans RJ, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost. 2012;108:160–5.
32. Laresche C, Pelletier F, Garnache-Ottou F, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol. 2014;134:176–82.
33. Toth B, Liebhardt S, Steinig K, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008;100:663–9.
34. Thaler J, Koder S, Kornek G, et al. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res. 2014;163:145–50.
35. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–82.
36. Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2012;30:3870–5.
37. Hong SK, Ko DW, Park J, et al. Alteration of antithrombin III and D-dimer levels in clinically localized prostate cancer. Korean J Urol. 2010;51:25–9.
38. Xu G, Zhang YL, Huang W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J Gastroenterol. 2004;10:922–3.
39. Byrne M, Reynolds JV, O’Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer. 2010;102:73–9.
40. Jeong O, Ryu SY, Park YK, et al. The effect of low molecular weight heparin thromboprophylaxis on bleeding complications after gastric cancer surgery. Ann Surg Oncol. 2010;17:2363–9.
41. Mita K, Ito H, Murabayashi R, et al. Postoperative bleeding complications after gastric cancer surgery in patients receiving anticoagulation and/or antiplatelet agents. Ann Surg Oncol. 2012;19:3745–52.
42. Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. Thromb Res. 2012;129:568–72.
43. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–9.
44. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–5.
45. Akl EA, Schünemann HJ. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med. 2012;366:661–2.
46. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.